Article: Other News To Note.

o Ablynx NV, of Ghent, Belgium, said it reached a settlement with Cambridge, UK-based Domantis Ltd. (now part of GlaxoSmithKline plc), concerning an alleged dispute relating to the companies' 2005 agreement. Under the new agreement, Ablynx has received a license to the European Winter II patent, which lay at the center of the dispute, and will pay Domantis low, single-digit royalties on the first five nanobody products that reach commercialization.

o Aquinox Pharmaceuticals Inc., of Vancouver, British Columbia, said it has selected AQX-1125 as its lead compound in its SH2-containing inositol phosphatase agonist program. Studies have commenced to support the ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!